Volume 7.07 | Feb 23

Newsletter Issue
Hematopoiesis News 7.07 February 23, 2016
Hematopoiesis News
     In this issue: Publications | Reviews | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  HN on Twitter
MLL-AF9- and HOXA9-Mediated Acute Myeloid Leukemia Stem Cell Self-Renewal Requires JMJD1C
Investigators determined that JMJD1C directly interacts with HOXA9 and modulates a HOXA9-controlled gene-expression program. In contrast, loss of JMJD1C led to only minor defects in blood homeostasis and modest effects on hematopoietic stem cells self-renewal. [J Clin Invest] Full Article
Get More of the Cells You Need with StemSpan™ Megakaryocyte Expansion Supplement and StemSpan™ SFEM
PUBLICATIONS (Ranked by impact factor of the journal)
Analysis of Jak2 Signaling Reveals Resistance of Mouse Embryonic Hematopoietic Stem Cells to Myeloproliferative Disease Mutation
The authors showed that the two cytokines interleukin 3 and thrombopoietin have the ability to expand hematopoietic stem and progenitor numbers by regulating their survival and proliferation. [Blood] Abstract

Ezh2 Controls an Early Hematopoietic Program and Growth and Survival Signaling in Early T Cell Precursor Acute Lymphoblastic Leukemia
Scientists studied the involvement of Ezh2 in a murine model of NRASQ61K-driven leukemia that recapitulates phenotypic and transcriptional features of early T cell precursor acute lymphoblastic leukemia. [Cell Rep] Full Article | Graphical Abstract | Press Release

β-Globin-Expressing Definitive Erythroid Progenitor Cells Generated from Embryonic and Induced Pluripotent Stem Cell-Derived Sacs
Researchers hypothesized that embryonic stem (ES) sacs serve as hemangioblast-like progenitors capable to generate definitive erythroid cells that express β-globin. With the ES sac-derived erythroid differentiation protocol, they obtained ∼120 erythroid cells per single ES cell. [Stem Cells] Abstract

Genetic Editing of HLA Expression in Hematopoietic Stem Cells to Broaden Their Human Application
Researchers sought to broaden the existing pool of registered unrelated donors based on analysis that eliminating the expression of the human leukocyte antigens (HLA)-A increases the chance for finding a donor matched at HLA-B, -C, and -DRB1 regardless of a patient’s race. Elimination of HLA-A expression in HSC was achieved using artificial zinc finger nucleases designed to target HLA-A alleles. [Sci Rep] Full Article

GATA Factor-G-Protein-Coupled Receptor Circuit Suppresses Hematopoiesis
Scientists demonstrated that GATA-2 rescued hematopoiesis in +9.5−/− aorta-gonad-mesonephros. As G-protein-coupled receptors (GPCRs) are the most common targets for FDA-approved drugs, they analyzed the GPCR gene ensemble to identify GATA-2-regulated GPCRs. [Stem Cell Reports]
Full Article | Graphical Abstract

Synergism between the mTOR Inhibitor Rapamycin and FAK Down-Regulation in the Treatment of Acute Lymphoblastic Leukemia
Researchers investigated whether the effect of the mammalian target of rapamycin (mTOR) inhibitor rapamycin is synergistic with the effect of focal adhesion kinase (FAK) down-regulation in the treatment of acute lymphoblastic leukemia. [J Hematol Oncol] Full Article

Cis-Vaccenic Acid Induces Differentiation and Up-Regulates Gamma Globin Synthesis in K562, JK1 and Transgenic Mice Erythroid Progenitor Stem Cells
The authors assayed the γ-globin inducing capacity of cis-vaccenic acid (CVA). CVA induced differentiation of K562, JK1 and transgenic mice primary bone marrow hematopoietic progenitor stem cells. [Eur J Pharmacol] Abstract


TGF- α and IL-6 Plasma Levels Selectively Identify CML Patients That Fail to Achieve an Early Molecular Response or Progress in the First Year of Therapy
Researchers employed multiplex cytokine profiling of plasma samples to test newly diagnosed chronic phase chronic myeloid leukemia (CP-CML) patients who subsequently received imatinib treatment. [Leukemia] Abstract

High Melphalan Exposure Is Associated with Improved Overall Survival in Myeloma Patients Receiving High Dose Melphalan and Autologous Transplantation
The authors determined whether high dose melphalan exposure is significantly associated with transplant outcomes. They demonstrated that high melphalan exposure is associated with improved survival, with an acceptable increase in transplant toxicity.[Br J Clin Pharmacol] Abstract

New Cord Banking Software Solution from STEMSOFT
Orchestration of B Lymphoid Cells and Their Inner Myeloid by Bach
The Bach2 gene regulatory networks support the myeloid-based model of hematopoiesis. Myeloid-like characteristics suppressed or manifested in B cells by modifying differentiation trajectories of B and myeloid cells may be termed as ‘inner myeloid’ after the concept of ‘inner fish’. [Curr Opin Immunol] Abstract

Visit our reviews page to see a complete list of reviews in the hematopoiesis research field.

ASGCT 2016 Annual Meeting
AVROBIO Inc. Launches to Develop Novel, Clinical-Stage Cell and Gene Therapies Targeting Immuno-Oncology and Rare Diseases
AVROBIO announced its launch plans to accelerate development of two novel cell and gene therapies. Phase I programs will be in the clinic by early to mid-2016 in both acute myeloid leukemia and Fabry disease. [AVROBIO Inc.] Press Release

CIRM Invests in Treatment Focused on High Risk Blood Cancers, Leukemia and Lymphoma
Cord blood transplants can be life saving for people battling deadly blood cancers, but they can also cause complications that are life-threatening. That’s why the California Institute for Regenerative Medicine (CIRM) has approved almost $3.5 million to fund a program to find a more effective, efficient and safer way to deliver those transplants. [California Institute for Regenerative Medicine] Press Release

Cutting Edge Medical Research Ideas Receive £23.2 Million Boost
The Medical Research Council is accelerating innovative medical research with £23.2 million in new funding to take ground-breaking ideas from UK universities into industry and out to patients. [Medical Research Council] Press Release

From our sponsor: Learn about detecting cancer stem cells with ALDEFLUOR™. Watch the webinar.
National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
NEW Gordon Research Conference – Notch Signaling in Development, Regeneration & Disease
July 31-August 5, 2016
Lewiston, United States

Visit our events page to see a complete list of events in the hematopoiesis community.
NEW Staff Scientist – Gene Regulation (Fred Hutchinson Cancer Research Center)

Postdoctoral Fellow – Hematopoietic Cell Fate and Gene Expression Control (University of Birmingham)

Lead Scientist – Translational Therapy (NHS Blood and Transplant)

PhD Position – Leukemogenesis and Treatment Resistance (Institute for Tumor Biology and Experimental Therapy)

Translational Research Scientist – Hematology/Oncology (University of Chicago)

Postdoctoral Associate – Epigenetic Regulation of Normal and Leukemic Stem Cells (Sanford Burnham Prebys Medical Discovery Institute)

Postdoctoral Researcher – Pre-Leukemic Stem Cells in the Thymus (Ghent University)

Laboratory Technician – Molecular Biology (Icahn School of Medicine at Mount Sinai)

Postdoctoral Scholarship – Cancer Biology (Lund University)

Assistant/Associate/Full Member Faculty – Myeloid Malignancies (Fred Hutchinson Cancer Research Center)

Recruit Top Talent: Reach more than 60,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Hematopoiesis News? Click here to submit!

Comments or suggestions? Submit your feedback here
Learn more about Hematopoiesis News: Archives | Events | Contact Us